UK Markets closed

Sarepta Therapeutics, Inc. (0L35.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
124.50-0.32 (-0.26%)
At close: 03:41PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3124.50
52-week low 3124.50
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 566.82M
Implied shares outstanding 6N/A
Float 883.62M
% held by insiders 14.40%
% held by institutions 184.59%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin -60.66%
Operating margin (ttm)-52.42%

Management effectiveness

Return on assets (ttm)-9.51%
Return on equity (ttm)-83.63%

Income statement

Revenue (ttm)835.18M
Revenue per share (ttm)9.81
Quarterly revenue growth (yoy)42.30%
Gross profit (ttm)-165.84M
EBITDA -396.65M
Net income avi to common (ttm)-506.63M
Diluted EPS (ttm)-7.11
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.93B
Total cash per share (mrq)22.02
Total debt (mrq)1.16B
Total debt/equity (mrq)159.22
Current ratio (mrq)4.53
Book value per share (mrq)9.60

Cash flow statement

Operating cash flow (ttm)-321.64M
Levered free cash flow (ttm)9.94M